Distinguishing Kidney Cancer Subtypes Using Raman Imaging


Brightfield image of the kidney tissue stained with hemotoxylin and eosin (H&E)
Brightfield image of the kidney tissue stained with hemotoxylin and eosin (H&E)
 
Raman chemical image showing unstained kidney tissue section
Raman chemical image showing unstained kidney tissue section

Discriminating important sub-types of kidney cancer can be very challenging using current pathological methods. This discrimination is important when there is a difference between benign and malignant kidney cancer, as treatment protocols will vary between the two types.

ChemImage’s Raman Molecular Imaging (RMI) approach enables differentiation between benign and malignant tissues which, using standard methods, appear to be the same.

Raman Molecular Imaging Of Kidney Cancer Can Provide:

  • Chemometric analysis and classification of cells
  • A clear discrimination between benign and malignant cells
  • Molecular-specific information displayed in the familiar format of a digital image
  • Non-destructive analysis of cells

An example of RMI in action includes the distinction of oncocytoma (a benign condition) and chromophobe renal cell carcinomas (a malignant condition). There are no established methods for discriminating between the two, even though treatment protocols vary based on type. Raman Molecular Imaging has been shown to definitively discriminate between the two types of carcinoma. This distinction can be used to create an accurate treatment plan.